AUT LibraryAUT
View Item 
  •   Open Research
  • AUT Faculties
  • Faculty of Health and Environmental Sciences
  • School of Science
  • View Item
  •   Open Research
  • AUT Faculties
  • Faculty of Health and Environmental Sciences
  • School of Science
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

COVID-19 Antibody Screening With SARS-CoV-2 Red Cell Kodecytes Using Routine Serologic Diagnostic Platforms

Nagappan, R; Flegel, WA; Srivastava, K; Williams, EC; Ryzhov, I; Tuzikov, A; Galanina, O; Shilova, N; Sukhikh, G; Perry, H; Bovin, NV; Henry, SM
Thumbnail
View/Open
Journal article (1.320Mb)
Permanent link
http://hdl.handle.net/10292/14122
Metadata
Show full metadata
Abstract
BACKGROUND: The COVID-19 pandemic is having a major global impact, and the resultant response in the development of new diagnostics is unprecedented. The detection of antibodies against SARS-CoV-2 has a role in managing the pandemic. We evaluated the feasibility of using SARS-CoV-2 peptide Kode Technology modified red cells (C19-kodecytes) to develop an assay compatible with existing routine serologic platforms. STUDY DESIGN AND METHODS: A panel of eight unique red cells modified using Kode Technology function-spacer-lipid constructs and bearing short SARS-CoV-2 peptides was developed (C19-kodecyte assay). Kodecytes were tested against undiluted expected antibody negative and positive plasma samples in manual tube and three column agglutination platforms. Parallel analysis with the same peptides in solid phase by enzyme immunoassays was performed. Evaluation samples included >120 expected negative blood donor samples and > 140 COVID-19 convalescent plasma samples, with independent serologic analysis from two centres. RESULTS: Specificity (reaction rate against expected negative samples) in three different column agglutionation (CAT) platforms against novel C19-kodecytes was >91%, which correlated with published literature. Sensitivity (reaction rate against expected positive convalescent, PCR confirmed samples) ranged from 82% to 97%, compared to 77% with the Abbott Architect SARS-CoV-2 IgG assay. Manual tube serology was less sensitive than CAT. Enzyme immuno assay results with some Kode Technology constructs also had high sensitivity. CONCLUSIONS: C19-kodecytes are viable for use as serologic reagent red cells for the detection of SARS-CoV-2 antibody with routine blood antibody screening equipment.
Keywords
Infectious disease testing; Intravenous immunoglobulin; Kodecyte
Date
2021
Source
Transfusion. 2021; 61: 1171– 1180. https://doi.org/10.1111/trf.16327
Item Type
Journal Article
Publisher
Wiley
DOI
10.1111/trf.16327
Publisher's Version
https://onlinelibrary.wiley.com/doi/10.1111/trf.16327
Rights Statement
© 2021 The Authors. Transfusion published by Wiley Periodicals LLC. on behalf of AABB. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Contact Us
  • Admin

Hosted by Tuwhera, an initiative of the Auckland University of Technology Library

 

 

Browse

Open ResearchTitlesAuthorsDateSchool of ScienceTitlesAuthorsDate

Alternative metrics

 

Statistics

For this itemFor all Open Research

Share

 
Follow @AUT_SC

Contact Us
  • Admin

Hosted by Tuwhera, an initiative of the Auckland University of Technology Library